Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma
previously considered to have a poor prognosis. Large gains were made in the first decade …

Signalling through the B cell receptor (BCR) is central to the development and maintenance
of B cells. In light of the numerous proliferative and survival pathways activated downstream …

Mantle cell lymphoma is a B cell malignancy in which constitutive dysregulation of cyclin D1
and the cell cycle, disruption of DNA damage response pathways, and activation of cell …

Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-
cells characterized by translocation, which is typically due to excess expression of Cyclin …

The B-cell receptor (BCR) is essential for normal B-cell development and maturation. In an
increasing number of B-cell malignancies, BCR signaling is implicated as a pivotal pathway …

Purpose Obinutuzumab (GA101), a type II, glycoengineered, humanized anti-CD20
monoclonal antibody, was superior to rituximab in human diffuse large B-cell lymphoma …

Purpose The combination of bendamustine (B) and rituximab (R) is efficacious, with
favorable toxicity in mantle-cell lymphoma (MCL). In this phase II study, we combined …

Mantle cell lymphoma (MCL) is a less frequent subtype of lymphoid malignancies and
represents 6%–9% of malignant lymphoma in Western Europe. The annual incidence of this …

The mTOR pathway plays a central role in many cellular processes, such as cellular growth,
protein synthesis, glucose, and lipid metabolism. Aberrant regulation of mTOR is a hallmark …

ABSTRACT Introduction: The phosphatidylinositide 3-kinase/AKT/mammalian target of
rapamycin (PI3K/AKT/mTOR) signaling pathway has emerged as an important target in …